Expression of p53, or targeting towards EGFR, enhances the oncolytic potency of conditionally replicative adenovirus against neuroblastoma

Birgit Geoerger, Victor W. van Beusechem, Paule Opolon, Jackie Morizet, Lysiane Laudani, Yann Lecluse, Michel Barrois, Sander Idema, Jacques Grill, Winald R. Gerritsen, Gilles Vassal

Research output: Contribution to journalArticle

Abstract

Background: Advanced stage and relapsing neuroblastoma (NB) has a poor prognosis with frequent treatment failures, warranting new treatment options and enhanced local tumor control. Treatment with conditionally replicative adenoviruses (CRAds) has shown effectiveness in various preclinical cancer models, but has not yet been evaluated for local control of NB. Here, we tested the efficacy of the CRAd AdΔ24 and of two AdΔ24 derivatives against NB. Derivative AdΔ24-425S11 infects cells deficient in coxsackie/adenovirus receptor (CAR) via the epidermal growth factor receptor (EGFR). Derivative AdΔ24-p53 expresses the tumor suppressor protein p53 to promote oncolysis. Methods: Expression of CAR and EGFR, and p53 pathway and DNA damage responses were analyzed in six NB cell lines and two xenografts derived from primary NB using immunohistochemistry, reporter gene transactivation, Western blot and fluorescence-activated cell sorting (FACS) analysis. Efficacy of AdΔ24, AdΔ24-425S11 and AdΔ24-p53 against NB was evaluated in vitro by cell viability analysis and in vivo by monitoring subcutaneous xenograft tumor growth in mice and by histological analysis of treated tumors. Results: Neuroblastoma cell lines were sensitive to oncolysis by AdΔ24, with a higher susceptibility of those with functional p53 and intact DNA damage responses. Compared to AdΔ24, AdΔ24-p53 exhibited enhanced oncolytic potency on all NB cell lines independent of their p53 status and AdΔ24-425S11 was more effective against CAR-low IGR-NB8 cells. Moreover, five daily intratumoral injections of 108 plaque-forming units (pfu) of AdΔ24-p53 or AdΔ24-425S11 into subcutaneous IGR-NB8 and IGR-N91 xenografts at an advanced tumor stage yielded significant tumor growth delays (TGD). In contrast, at this dose, AdΔ24 did not cause significant TGD of neuroblastoma xenografts. Injection of AdΔ24-p53 was associated with extensive cell lysis, apoptotic cell death, and fibrous fascicles in the tumors. Conclusion. CRAds expressing p53 and targeted towards EGFR appear promising new agents for local control in the treatment of neuroblastoma.

Original languageEnglish (US)
Pages (from-to)584-594
Number of pages11
JournalJournal of Gene Medicine
Volume7
Issue number5
DOIs
StatePublished - May 2005
Externally publishedYes

Fingerprint

Neuroblastoma
Epidermal Growth Factor Receptor
Adenoviridae
Coxsackie and Adenovirus Receptor-Like Membrane Protein
Heterografts
Neoplasms
Cell Line
DNA Damage
Growth
Tumor Suppressor Protein p53
Injections
Treatment Failure
Reporter Genes
Transcriptional Activation
Cell Survival
Flow Cytometry
Cell Death
Therapeutics
Western Blotting
Immunohistochemistry

Keywords

  • Adenovirus
  • EGFR
  • Neuroblastoma xenografts
  • Oncolysis
  • p53

ASJC Scopus subject areas

  • Genetics

Cite this

Geoerger, B., van Beusechem, V. W., Opolon, P., Morizet, J., Laudani, L., Lecluse, Y., ... Vassal, G. (2005). Expression of p53, or targeting towards EGFR, enhances the oncolytic potency of conditionally replicative adenovirus against neuroblastoma. Journal of Gene Medicine, 7(5), 584-594. https://doi.org/10.1002/jgm.703

Expression of p53, or targeting towards EGFR, enhances the oncolytic potency of conditionally replicative adenovirus against neuroblastoma. / Geoerger, Birgit; van Beusechem, Victor W.; Opolon, Paule; Morizet, Jackie; Laudani, Lysiane; Lecluse, Yann; Barrois, Michel; Idema, Sander; Grill, Jacques; Gerritsen, Winald R.; Vassal, Gilles.

In: Journal of Gene Medicine, Vol. 7, No. 5, 05.2005, p. 584-594.

Research output: Contribution to journalArticle

Geoerger, B, van Beusechem, VW, Opolon, P, Morizet, J, Laudani, L, Lecluse, Y, Barrois, M, Idema, S, Grill, J, Gerritsen, WR & Vassal, G 2005, 'Expression of p53, or targeting towards EGFR, enhances the oncolytic potency of conditionally replicative adenovirus against neuroblastoma', Journal of Gene Medicine, vol. 7, no. 5, pp. 584-594. https://doi.org/10.1002/jgm.703
Geoerger, Birgit ; van Beusechem, Victor W. ; Opolon, Paule ; Morizet, Jackie ; Laudani, Lysiane ; Lecluse, Yann ; Barrois, Michel ; Idema, Sander ; Grill, Jacques ; Gerritsen, Winald R. ; Vassal, Gilles. / Expression of p53, or targeting towards EGFR, enhances the oncolytic potency of conditionally replicative adenovirus against neuroblastoma. In: Journal of Gene Medicine. 2005 ; Vol. 7, No. 5. pp. 584-594.
@article{2265cb043ec94e1aa6e3527d99388d0a,
title = "Expression of p53, or targeting towards EGFR, enhances the oncolytic potency of conditionally replicative adenovirus against neuroblastoma",
abstract = "Background: Advanced stage and relapsing neuroblastoma (NB) has a poor prognosis with frequent treatment failures, warranting new treatment options and enhanced local tumor control. Treatment with conditionally replicative adenoviruses (CRAds) has shown effectiveness in various preclinical cancer models, but has not yet been evaluated for local control of NB. Here, we tested the efficacy of the CRAd AdΔ24 and of two AdΔ24 derivatives against NB. Derivative AdΔ24-425S11 infects cells deficient in coxsackie/adenovirus receptor (CAR) via the epidermal growth factor receptor (EGFR). Derivative AdΔ24-p53 expresses the tumor suppressor protein p53 to promote oncolysis. Methods: Expression of CAR and EGFR, and p53 pathway and DNA damage responses were analyzed in six NB cell lines and two xenografts derived from primary NB using immunohistochemistry, reporter gene transactivation, Western blot and fluorescence-activated cell sorting (FACS) analysis. Efficacy of AdΔ24, AdΔ24-425S11 and AdΔ24-p53 against NB was evaluated in vitro by cell viability analysis and in vivo by monitoring subcutaneous xenograft tumor growth in mice and by histological analysis of treated tumors. Results: Neuroblastoma cell lines were sensitive to oncolysis by AdΔ24, with a higher susceptibility of those with functional p53 and intact DNA damage responses. Compared to AdΔ24, AdΔ24-p53 exhibited enhanced oncolytic potency on all NB cell lines independent of their p53 status and AdΔ24-425S11 was more effective against CAR-low IGR-NB8 cells. Moreover, five daily intratumoral injections of 108 plaque-forming units (pfu) of AdΔ24-p53 or AdΔ24-425S11 into subcutaneous IGR-NB8 and IGR-N91 xenografts at an advanced tumor stage yielded significant tumor growth delays (TGD). In contrast, at this dose, AdΔ24 did not cause significant TGD of neuroblastoma xenografts. Injection of AdΔ24-p53 was associated with extensive cell lysis, apoptotic cell death, and fibrous fascicles in the tumors. Conclusion. CRAds expressing p53 and targeted towards EGFR appear promising new agents for local control in the treatment of neuroblastoma.",
keywords = "Adenovirus, EGFR, Neuroblastoma xenografts, Oncolysis, p53",
author = "Birgit Geoerger and {van Beusechem}, {Victor W.} and Paule Opolon and Jackie Morizet and Lysiane Laudani and Yann Lecluse and Michel Barrois and Sander Idema and Jacques Grill and Gerritsen, {Winald R.} and Gilles Vassal",
year = "2005",
month = "5",
doi = "10.1002/jgm.703",
language = "English (US)",
volume = "7",
pages = "584--594",
journal = "Journal of Gene Medicine",
issn = "1099-498X",
publisher = "John Wiley and Sons Ltd",
number = "5",

}

TY - JOUR

T1 - Expression of p53, or targeting towards EGFR, enhances the oncolytic potency of conditionally replicative adenovirus against neuroblastoma

AU - Geoerger, Birgit

AU - van Beusechem, Victor W.

AU - Opolon, Paule

AU - Morizet, Jackie

AU - Laudani, Lysiane

AU - Lecluse, Yann

AU - Barrois, Michel

AU - Idema, Sander

AU - Grill, Jacques

AU - Gerritsen, Winald R.

AU - Vassal, Gilles

PY - 2005/5

Y1 - 2005/5

N2 - Background: Advanced stage and relapsing neuroblastoma (NB) has a poor prognosis with frequent treatment failures, warranting new treatment options and enhanced local tumor control. Treatment with conditionally replicative adenoviruses (CRAds) has shown effectiveness in various preclinical cancer models, but has not yet been evaluated for local control of NB. Here, we tested the efficacy of the CRAd AdΔ24 and of two AdΔ24 derivatives against NB. Derivative AdΔ24-425S11 infects cells deficient in coxsackie/adenovirus receptor (CAR) via the epidermal growth factor receptor (EGFR). Derivative AdΔ24-p53 expresses the tumor suppressor protein p53 to promote oncolysis. Methods: Expression of CAR and EGFR, and p53 pathway and DNA damage responses were analyzed in six NB cell lines and two xenografts derived from primary NB using immunohistochemistry, reporter gene transactivation, Western blot and fluorescence-activated cell sorting (FACS) analysis. Efficacy of AdΔ24, AdΔ24-425S11 and AdΔ24-p53 against NB was evaluated in vitro by cell viability analysis and in vivo by monitoring subcutaneous xenograft tumor growth in mice and by histological analysis of treated tumors. Results: Neuroblastoma cell lines were sensitive to oncolysis by AdΔ24, with a higher susceptibility of those with functional p53 and intact DNA damage responses. Compared to AdΔ24, AdΔ24-p53 exhibited enhanced oncolytic potency on all NB cell lines independent of their p53 status and AdΔ24-425S11 was more effective against CAR-low IGR-NB8 cells. Moreover, five daily intratumoral injections of 108 plaque-forming units (pfu) of AdΔ24-p53 or AdΔ24-425S11 into subcutaneous IGR-NB8 and IGR-N91 xenografts at an advanced tumor stage yielded significant tumor growth delays (TGD). In contrast, at this dose, AdΔ24 did not cause significant TGD of neuroblastoma xenografts. Injection of AdΔ24-p53 was associated with extensive cell lysis, apoptotic cell death, and fibrous fascicles in the tumors. Conclusion. CRAds expressing p53 and targeted towards EGFR appear promising new agents for local control in the treatment of neuroblastoma.

AB - Background: Advanced stage and relapsing neuroblastoma (NB) has a poor prognosis with frequent treatment failures, warranting new treatment options and enhanced local tumor control. Treatment with conditionally replicative adenoviruses (CRAds) has shown effectiveness in various preclinical cancer models, but has not yet been evaluated for local control of NB. Here, we tested the efficacy of the CRAd AdΔ24 and of two AdΔ24 derivatives against NB. Derivative AdΔ24-425S11 infects cells deficient in coxsackie/adenovirus receptor (CAR) via the epidermal growth factor receptor (EGFR). Derivative AdΔ24-p53 expresses the tumor suppressor protein p53 to promote oncolysis. Methods: Expression of CAR and EGFR, and p53 pathway and DNA damage responses were analyzed in six NB cell lines and two xenografts derived from primary NB using immunohistochemistry, reporter gene transactivation, Western blot and fluorescence-activated cell sorting (FACS) analysis. Efficacy of AdΔ24, AdΔ24-425S11 and AdΔ24-p53 against NB was evaluated in vitro by cell viability analysis and in vivo by monitoring subcutaneous xenograft tumor growth in mice and by histological analysis of treated tumors. Results: Neuroblastoma cell lines were sensitive to oncolysis by AdΔ24, with a higher susceptibility of those with functional p53 and intact DNA damage responses. Compared to AdΔ24, AdΔ24-p53 exhibited enhanced oncolytic potency on all NB cell lines independent of their p53 status and AdΔ24-425S11 was more effective against CAR-low IGR-NB8 cells. Moreover, five daily intratumoral injections of 108 plaque-forming units (pfu) of AdΔ24-p53 or AdΔ24-425S11 into subcutaneous IGR-NB8 and IGR-N91 xenografts at an advanced tumor stage yielded significant tumor growth delays (TGD). In contrast, at this dose, AdΔ24 did not cause significant TGD of neuroblastoma xenografts. Injection of AdΔ24-p53 was associated with extensive cell lysis, apoptotic cell death, and fibrous fascicles in the tumors. Conclusion. CRAds expressing p53 and targeted towards EGFR appear promising new agents for local control in the treatment of neuroblastoma.

KW - Adenovirus

KW - EGFR

KW - Neuroblastoma xenografts

KW - Oncolysis

KW - p53

UR - http://www.scopus.com/inward/record.url?scp=21144459195&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21144459195&partnerID=8YFLogxK

U2 - 10.1002/jgm.703

DO - 10.1002/jgm.703

M3 - Article

C2 - 15651070

AN - SCOPUS:21144459195

VL - 7

SP - 584

EP - 594

JO - Journal of Gene Medicine

JF - Journal of Gene Medicine

SN - 1099-498X

IS - 5

ER -